PROGRAM LICENSING

Nuevolution’s present objectives are to develop several attractive small molecule programs up to a clinical Candidate or to an early clinical stage. We embrace partnerships to advance novel promising programs rapidly through clinical development to commercialization and provide treatment benefit for the patients.

Nuevolution has successfully applied its drug discovery platform to establish a portfolio of internal pipeline programs within oncology, immuno-oncology and inflammatory (autoimmune) diseases

Our current programs available for partnering are:

  • RORγt – Orally available RORγt inverse agonists for inflammatory diseases
  • BET-BRD – First-in-class BET domain selective bromodomain 1 inhibitors
  • IL-17A – First-in-class IL17A small molecule (topical & systemic) program targeting inflammatory diseases

Further information on our pipeline projects is available in the pipeline section.

RECENT Partnerships

Read more

The Almirall and Nuevolution partnership is a global strategic collaboration focusing on the development and commercialization of Nuevolution’s novel RORgt inverse agonist (inhibitor) program for treatment of inflammatory skin diseases and disorders as well as for treatment of psoriatic arthritis. Both parties will work in this research collaboration towards to successful identification of additional RORgt inhibitors, where Almirall has an exclusive option for use within dermatology and where Nuevolution has optional use in areas outside the field of collaboration.

OUR PARTNERS

almirall_125_sepia
Amgen_Logo_Sepia_125
JJ_sephia_250
Merck_250_sepia
bric_logo_125_sepia
gsk_250_sepia
ICR_250_sepia
HHMI_logo_250_sepia